$63.88−0.05 (−0.08%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Eton Pharmaceuticals (ETON) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
2 figures withheld by our checks. Each blank figure names its reason.
Business engineGrowing fast: revenue compounds ~38.3%/yr (FY21→FY25), net margin −5.8%. Worth your attention in FY25: Share count (+8.2%) and Capex step-up ($333.0K). Both visible in the receipts below.
The lines that matter · FY21–FY25
Revenue ($M)▲104.9%
80.0
FY21→FY25CAGR +38.3%/yr
Net income ($M)▼20.4%
−4.6
one-off year: see footnoteCAGR —
Free cash flow ($M)▲980.7%
10.2
capex stepped upCAGR —
What the receipts whisper · what a headline number hides
Share count
+8.2%
25.2mn → 27.3mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$333.0K
▲1181% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)
-6¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Net margin -5.8% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 141,061.0 | 79,950.0 | 39,011.0 | 31,642.0 | 21,251.0 | 21,832.0 | ▲104.9% | +38.3% |
Cost of revenue | 43,512.0 | 37,210.0 | 15,600.0 | 10,581.0 | 6,933.0 | 2,827.0 | ▲138.5% | +90.5% |
Gross profit | 97,549.0 | 42,740.0 | 23,411.0 | 21,061.0 | 14,318.0 | —A | ▲82.6% | +44.0% |
Research & development | 9,919.0 | 7,765.0 | 3,255.0 | 3,322.0 | 3,996.0 | 6,235.0 | ▲138.6% | +5.6% |
Selling, general & admin | 46,945.0 | 35,819.0 | 22,753.0 | 18,931.0 | 18,582.0 | 14,265.0 | ▲57.4% | +25.9% |
Total operating expenses | 56,864.0 | 43,584.0 | 26,008.0 | 22,253.0 | 22,578.0 | 20,500.0 | ▲67.6% | +20.8% |
Operating incomefeeds ROC rank | 40,685.0 | −844.0 | −2,597.0 | −1,192.0 | −8,260.0 | −1,495.0 | ▲67.5% | — |
Other income, net | −3,622.0 | −3,714.0 | −1,211.0 | 503.0 | −761.0 | −460.0 | — | — |
Pretax income | 37,063.0 | −4,558.0 | −3,808.0 | −689.0 | −9,021.0 | −1,955.0 | ▼19.7% | — |
Income tax | −12,801.0 | 43.0 | 15.0 | 247.0 | 0.0 | 0.0 | ▲186.7% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | 49,864.0 | −4,601.0 | −3,823.0 | −936.0 | −9,021.0 | −1,955.0 | ▼20.4% | — |
| Per share | ||||||||
Diluted shares (mn) | 33.26 | 27.28 | 26.82 | 25.69 | 25.46 | 25.21 | ▲1.7% | +2.0% |
| Margins | ||||||||
Gross margin56th pct in Healthcare | 69.2% | 53.5% | 60.0% | 66.6% | 67.4% | —A | ▼6.6pp | −13.9pp |
Operating margin | 28.8% | −1.1% | −6.7% | −3.8% | −38.9% | −6.8% | ▲5.6pp | +5.8pp |
Net margin97th pct in Healthcare | 35.3% | −5.8% | −9.8% | −3.0% | −42.4% | −9.0% | ▲4.0pp | +3.2pp |
† TTM = trailing four quarters through 2026-09-30.FY23 effective tax rate was −36% vs a −0% norm for this window, likely a one-time item; see the filing.A Withheld: this year's gross margin is not on the same cost basis as the earlier years.
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-19 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Eton Pharmaceuticals' revenue last fiscal year?
Eton Pharmaceuticals reported revenue of $80.0M in fiscal 2025, up 104.9% from fiscal 2024.
What was Eton Pharmaceuticals' net income?
Eton Pharmaceuticals reported net income of −$4.6M in fiscal 2025, a net margin of −5.8%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

